Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA Approves Valcyte to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants

By Pharmaceutical Processing | August 31, 2009

Roche announced today that the FDAhas approved Valcyte (valganciclovir hydrochloride) for the prevention ofcytomegalovirus (CMV) disease in pediatric kidney and heart transplantpatients (4 months to 16 years of age) at high risk of developing CMV disease.The FDA also approved a new pediatric oral solution formulation for Valcyte,which will allow easier administration to pediatric patients 4 months to 16years of age. “Children receiving organ transplants are especially vulnerable toinfection because of their reduced immunity, and the invasive procedure of atransplant can put them at higher risk of contracting CMV infection,” notedRichard Freeman, M.D., Vice Chair for Research, Department of Surgery,Professor of Surgery, Tufts Medical Center. “Prevention and medication dosingcan be challenging because children are not small adults. The new oralformulation and information about how to administer the medicine will helpdoctors treat their pediatric transplant patients.” CMV (herpesvirus) infects approximately 80 percent of the U.S. populationdepending on age. In the majority of cases the virus lies dormant in the bodythroughout life, but can be reactivated at times when the immune system isweakened (such as transplant patients and AIDS patients). In patients whohave received an organ transplant, CMV infection usually develops during thefirst few months after transplantation, and may cause complications in thelungs, kidneys, nervous system, liver, and gastrointestinal tract. CMV canlead to the loss of the transplanted organ, and studies have shown that thevirus has been correlated with an increased risk of death in post-transplantpatients. Over the past 21 years, more than 35,000 children ages 17 and younger havebeen transplant recipients in the U.S. Before preventative measures weretaken to reduce the risk of infection, CMV among pediatric transplant patientswas found in 26 percent of thoracic organ and 22 percent of kidney recipients.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards